top of page
Daylight logo.png
Wider therapeutic window v4.png

Best-in-class immune engagers for solid tumors

CREATING DAYLIGHT BETWEEN EFFICACY AND TOXICITY

About Us

Founded August 2025 with technology licensed from Seattle Children's Research Institute

Our Vision

At Daylight Biotherapeutics we are decoupling tumor killing from systemic immune activation using our novel  T cell engaging technology. Our mission is to harness the natural power of the immune system to create safer more effective treatments for patients with cancer.

Daylight_9135.jpg

Company News

AACR 2026 Poster

Daylight Bio and the SCRI team traveled to sunny San Diego in April for the 2026 AACR  meeting where they presented poster #4487 "Novel CD3 binders enable T cell engagers with potent tumor control, limited cytokine release, and safe pairing with co-stimulation" 

Contact Us

Reach Out to Our Team

Let's Collaborate to Innovate

bottom of page